Vectura Group Plc (VEC) - Financial and Strategic SWOT Analysis Review

1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Consort Medical plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • Vernalis Plc
  • MORE
Vectura Group Plc (VEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases. The company develops products based on a wide range of proprietary lung delivery technologies, including device and formulation capabilities. Vectura has a varied portfolio of drugs in clinical development, comprising several novel and generic programs that are partnered with several global biotechnology and pharmaceutical companies. Vectura is headquartered in Chippenham, Wiltshire, the UK.

Vectura Group Plc Key Recent Developments

Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director
Apr 20, 2018: Vectura Announces Senior Management Change
Apr 20, 2018: Vectura Group: Directorate Change - Chief Financial Officer
Mar 21, 2018: Vectura Group: 2017 Preliminary Results
Mar 21, 2018: Vectura Group: 2017 Preliminary Results - Performance in-line with expectations, with strong in-market growth from key inhaled products

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Consort Medical plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • Vernalis Plc
  • MORE
Section 1 - About the Company
  • Vectura Group Plc - Key Facts
  • Vectura Group Plc - Key Employees
  • Vectura Group Plc - Key Employee Biographies
  • Vectura Group Plc - Major Products and Services
  • Vectura Group Plc - History
  • Vectura Group Plc - Company Statement
  • Vectura Group Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Vectura Group Plc - Business Description
  • Vectura Group Plc - Corporate Strategy
  • Vectura Group Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Vectura Group Plc - Strengths
  • Vectura Group Plc - Weaknesses
  • Vectura Group Plc - Opportunities
  • Vectura Group Plc - Threats
  • Vectura Group Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Vectura Group Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 20, 2018: Vectura Group: Directorate Change - Chief Financial Officer
  • Mar 21, 2018: Vectura Group: 2017 Preliminary Results
  • Mar 21, 2018: Vectura Group: 2017 Preliminary Results - Performance in-line with expectations, with strong in-market growth from key inhaled products
  • Nov 29, 2017: Vectura Group appoints Juliet Thompson to its Board of Directors
  • Oct 24, 2017: Vectura Group: Ultibro Breezhaler continues to deliver strong underlying growth in Q3
  • Sep 06, 2017: Vectura Group: 2017 Interim Results
  • Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016
  • Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016
  • Mar 06, 2017: Vectura Group: Board Change
  • Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Vectura Group Plc, Key Facts
  • Vectura Group Plc, Key Employees
  • Vectura Group Plc, Key Employee Biographies
  • Vectura Group Plc, Major Products and Services
  • Vectura Group Plc, History
  • Vectura Group Plc, Subsidiaries
  • Vectura Group Plc, Key Competitors
  • Vectura Group Plc, Ratios based on current share price
  • Vectura Group Plc, Annual Ratios
  • Vectura Group Plc, Annual Ratios (Cont...1)
  • Vectura Group Plc, Annual Ratios (Cont...2)
  • Vectura Group Plc, Interim Ratios
  • Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Vectura Group Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Vectura Group Plc, Performance Chart (2013 - 2017)
  • Vectura Group Plc, Ratio Charts
  • Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Vernalis Plc
  • Novartis AG
  • GlaxoSmithKline Plc
  • Consort Medical plc
  • AstraZeneca Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll